Science

CSIR identifies top drug candidates for repurposing

India Science Wire New Delhi | Updated on April 30, 2020 Published on April 30, 2020

csir-chennai

The Council for Scientific and Industrial Research (CSIR) has been leading the fight against Covid-19 epidemic on multiple fronts. Among those, the Council has laid significant emphasis on repurposed drugs as they can be quickly deployed for treatment as opposed to new drugs, which need almost a decade of development. Globally, many drugs are under clinical trials on coronavirus patients to establish their efficacy against Covid-19.

Towards providing drugs for coronavirus patients in India, CSIR has identified 25 drugs/drug candidates for repurposing. Among these 25 drugs, Favipiravir - a broad-spectrum inhibitor of viral RNA polymerase - has emerged as one of the most promising drugs. Favipiravir was developed by Fujifilm Toyama Chemical Ltd., and is an approved treatment for common influenza and is marketed in Russia, China and Japan.

CSIR-IICT, based in Hyderabad, has developed a convenient and cost-effective synthetic process for Favipiravir. As a collaborative effort with industry, CSIR-IICT transferred the entire process and significant quantities of active pharmaceutical ingredient (API) of Favipiravir to Cipla, a leading pharmaceutical company. Cipla will be conducting the investigations before the launching of this drug against Covid-19 in India. Cipla has already approached the Drug Controller General of India (DCGI), the regulatory authority, for its approval of Favipiravir to be launched in India. Favipiravir is a generic drug and already being used for the treatment of influenza and is also in clinical trials for Covid-19 in many countries such as China, Japan and Italy. Under the auspices of the Indian Council of Medical Research (ICMR), Cipla will conduct a suitable limited trial prior to marketing the product as Ciplenza.

CSIR and Cipla have a long history of working together for affordable drugs in India and overseas. Many of the technologies for HIV generic drugs were established at CSIR labs. and Cipla was successful in providing affordable treatment to HIV patients worldwide, which led to saving millions of lives. They have assured the government that they will do the same for Favirpiravir.

Twitter handle: @indianscinews

Published on April 30, 2020

A letter from the Editor


Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!

Sincerely,

Support Quality Journalism
This article is closed for comments.
Please Email the Editor
You have read 1 out of 3 free articles for this week. For full access, please subscribe and get unlimited access to all sections.